Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "BLA"

267 News Found

Lonza announces expansion plans for mammalian manufacturing facilities
News | May 07, 2021

Lonza announces expansion plans for mammalian manufacturing facilities

The facility is expected to be completed in 2024


Govt. allocates 16.5 lakh vials of Remdesivir between May 3-9
News | May 06, 2021

Govt. allocates 16.5 lakh vials of Remdesivir between May 3-9

Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago


Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
Biotech | April 28, 2021

Biocon and Viatris receive EC approval for Biosimilar Bevacizumab

The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer


From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar
News | March 10, 2021

From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar

Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12
News | February 11, 2021

ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12

Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business